BRUNETTO, MAURIZIA ROSSANA
 Distribuzione geografica
Continente #
NA - Nord America 402
EU - Europa 92
AS - Asia 29
AF - Africa 7
SA - Sud America 1
Totale 531
Nazione #
US - Stati Uniti d'America 398
FR - Francia 28
IT - Italia 25
DE - Germania 12
CN - Cina 8
VN - Vietnam 8
FI - Finlandia 6
IN - India 6
CA - Canada 4
RU - Federazione Russa 4
ZA - Sudafrica 4
GB - Regno Unito 3
NL - Olanda 3
BE - Belgio 2
DZ - Algeria 2
RO - Romania 2
SE - Svezia 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
GR - Grecia 1
IE - Irlanda 1
KR - Corea 1
MA - Marocco 1
PH - Filippine 1
PK - Pakistan 1
SG - Singapore 1
TH - Thailandia 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 531
Città #
Fairfield 41
Santa Cruz 38
Houston 29
Ashburn 25
Buffalo 24
Seattle 23
Woodbridge 20
Ann Arbor 18
Serra 16
Cambridge 10
Wilmington 10
Des Moines 7
Las Vegas 7
Bengaluru 6
Chicago 4
Dong Ket 4
Henderson 4
Mountain View 4
San Diego 4
Beijing 3
Boardman 3
Helsinki 3
Lappeenranta 3
Muizenberg 3
New York 3
Phoenix 3
Provo 3
Saint Petersburg 3
San Francisco 3
Brussels 2
Hangzhou 2
Herndon 2
Ottawa 2
Portland 2
Shanghai 2
Stockholm 2
Algiers 1
Altlußheim 1
Amsterdam 1
Auburn 1
Bangkok 1
Bologna 1
Boulder 1
Büdelsdorf 1
Clearwater 1
Council Bluffs 1
Crugers 1
Dublin 1
El Jadida 1
Esslingen am Neckar 1
Faisalabad 1
Fleming Island 1
Frankfurt am Main 1
Fremont 1
Guelph 1
Iasi 1
Jersey City 1
Kirkland 1
Madrid 1
Mount Vernon 1
Paris 1
Peccioli 1
Pisa 1
Providence 1
Rome 1
Scarlino 1
Silverton 1
Skikda 1
Southend 1
Southwark 1
Tashkent 1
Thessaloníki 1
Toronto 1
Wuhan 1
Totale 376
Nome #
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways, file e0d6c929-a842-fcf8-e053-d805fe0aa794 105
null, file e0d6c929-fd21-fcf8-e053-d805fe0aa794 105
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease, file e0d6c92c-7ed1-fcf8-e053-d805fe0aa794 98
Hepatitis B Virus RNA Detection and a Mindful Use of Serum Hepatitis B Virus DNA and Hepatitis B Surface Antigen Measures in Clinical Practice., file e0d6c92f-ae42-fcf8-e053-d805fe0aa794 59
Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis., file e0d6c92f-c890-fcf8-e053-d805fe0aa794 54
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network, file e0d6c929-ec14-fcf8-e053-d805fe0aa794 45
A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection., file e0d6c92c-a58b-fcf8-e053-d805fe0aa794 44
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort, file e0d6c92d-7047-fcf8-e053-d805fe0aa794 11
E-Nose for the Monitoring of Severe Liver Impairment: A Preliminary Study., file e0d6c932-1a5d-fcf8-e053-d805fe0aa794 10
The role of quantitative hepatitis B surface antigen revisited, file e0d6c92c-a592-fcf8-e053-d805fe0aa794 9
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research, file e0d6c92a-ea6c-fcf8-e053-d805fe0aa794 7
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B., file e0d6c92c-6d0e-fcf8-e053-d805fe0aa794 3
Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma, file cfb609af-a138-4912-879c-4cbf57e8cc65 2
null, file e0d6c92c-69d1-fcf8-e053-d805fe0aa794 2
null, file e0d6c92d-2618-fcf8-e053-d805fe0aa794 2
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF), file e0d6c92d-762c-fcf8-e053-d805fe0aa794 2
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths, file e0d6c928-0325-fcf8-e053-d805fe0aa794 1
null, file e0d6c92c-7b41-fcf8-e053-d805fe0aa794 1
null, file e0d6c92c-7b47-fcf8-e053-d805fe0aa794 1
null, file e0d6c92c-8bfa-fcf8-e053-d805fe0aa794 1
null, file e0d6c92c-8bff-fcf8-e053-d805fe0aa794 1
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach, file e0d6c931-6089-fcf8-e053-d805fe0aa794 1
Totale 564
Categoria #
all - tutte 1.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.544


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201932 0 0 0 0 0 0 0 0 0 7 14 11
2019/202077 8 14 3 4 7 8 8 6 6 4 6 3
2020/202168 2 5 1 3 2 6 10 5 9 4 11 10
2021/2022174 11 6 5 22 23 9 7 10 9 10 45 17
2022/2023139 4 15 48 24 9 17 5 2 1 4 8 2
2023/202459 4 2 4 3 20 8 7 8 1 2 0 0
Totale 564